| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Further information | Nov 15 This appraisal is suspended following an update from the company (Pfizer) that the situation regarding ISS has changed and they do not have any current plans to file for the ISS indication for genotropin. |
| Process | TA |
| ID number | 317 |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 27 November 2015 | Discontinued |
For further information on how we select topics for development, please see our page about topic selection